Abstract
AbstractRecent drug safety concerns described fluoroquinolone (FQ)-induced serious musculoskeletal reactions. The objective of this study was to characterize reports with FQ-associated disabling musculoskeletal disorders, from VigiBase. The analysis included all FQ-induced musculoskeletal and connective tissue disorders adverse drug reaction (ADR) reports (up to July-2019), (disabling/incapacitating, or recovered/resolved with sequelae or fatal). We described aspects like reporter, suspected FQs, ADRs, associated corticosteroid therapy. We also looked into the disproportionality data in terms of proportional reporting ratio (PRR) and information component (IC) values. A total of 5355 reports with 13,563 ADRs and 5558 FQs were reported. The majority of reports were for patients aged 18–64 (62.67%), and the female gender prevailed (61.76%). Consumers reported almost half (45.99%), with a peak in reporting rates in 2017. Top reported ADRs were arthralgia (16.34%), tendonitis (11.04%), pain in extremity (9.98%), tendon pain (7.63%), and myalgia (7.17%). Top suspected FQs were levofloxacin (50.04%), ciprofloxacin (38.41%), moxifloxacin (5.16%), ofloxacin (3.17%) and norfloxacin (1.01%). For these, FQs-ADR association was supported by the disproportionality analysis. Corticosteroids were associated with about 7% of tendon related reports. The results augment the existing data on FQs safety concerns, specifically their potential effect on the musculoskeletal system.
Funder
Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Conforti, A. et al. Musculoskeletal adverse drug reactions: A review of literature and data from adr spontaneous reporting databases. Curr. Drug Saf. 2(1), 47–63 (2008).
2. Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72(6), 905–908 (2011).
3. European Medicines Agency: EMA/818158/2018. Pharmacovigilance Risk Assessment Committee (PRAC), 16 October 2018. Assessment Report. Referral Under Article 31 of Directive 2001/83/EC Resulting from Pharmacovigilance Data. https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-assessment-report_en.pdf (2018).
4. Sendzik, J., Lode, H. & Stahlmann, R. Quinolone-induced arthropathy: An update focusing on new mechanistic and clinical data. Int. J. Antimicrob. Agents. 33(3), 194–200 (2009).
5. Patterson, D. R. Quinolone toxicity: Methods of assessment. Am. J. Med. 91(6A), 35S-37S (1991).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献